Regeneron Pharmaceuticals (REGN) has secured a landmark FDA approval for its monoclonal antibody garetosmab, now commercially known as Pasatru, after more than ten years in development. The drug becomes the second FDA-cleared
The European Union has adopted its first substantive amendment to the AI Act, marking a significant moment in the bloc’s evolving artificial intelligence regulatory framework. Regulation (EU) 2026/1744, commonly known as the
More
Investors seeking passive income have more options than ever, but choosing between cash savings and dividend stocks requires careful thought about risk and reward. Interest rates in the UK are expected to
More
Encompass Health (NYSE: EHC) has drawn renewed investor attention following a broader review of first-quarter results across outpatient and specialty care stocks. The outpatient and specialty care sector remains one of the
More
Manchester United’s proposed 100,000-seat stadium represents one of the largest sports infrastructure projects currently under consideration in Europe. The development is intended to become the centrepiece of a wider regeneration of the
More
Pharmaceutical supply chains face mounting pressure to maintain precise product traceability at every stage of the distribution process. Aggregation, the process of linking serialised items to their parent containers, has emerged as
More
The US Biglaw associate compensation market is moving fast, with firms rapidly matching a new $235K salary scale that Milbank first introduced on Tuesday, June 2, 2026. The new benchmark has triggered
More
LGEN shares are drawing fresh attention from income-focused investors seeking reliable dividend returns in an uncertain market environment. Legal & General, the FTSE 100 insurer listed on the London Stock Exchange under
More
The UK stock market has been shrinking for years, with fewer listed companies and reduced market capitalisation raising serious concerns among investors and analysts alike. London’s stock exchange has seen a notable
More
Karyopharm Therapeutics has suffered a severe blow after its flagship drug selinexor, sold as Xpovio, failed to meet its primary endpoint in a Phase 3 endometrial cancer trial. The XPORT-EC-042 trial evaluated
More
California’s Proposition 65, formally known as the Safe Drinking Water and Toxic Enforcement Act of 1986, continues to generate significant litigation pressure on businesses selling products in the state. The law requires
More